Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10555935 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

Patent 10555935 was granted and assigned to FORMA Therapeutics on February, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

FORMA Therapeutics

0

Current Assignee

FORMA Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Xiaozhang Zheng0

Mary-Margaret Zablocki0

Pui Yee Ng0

Date of Patent

February 11, 2020

0

Patent Application Number

163099800

Date Filed

June 16, 2017

0

Patent Citations

US Patent 10377726 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 10414738 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 10407418 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

US Patent 10112915 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 10183934 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

0

US Patent 10214500 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 10214501 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 10239845 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

Patent Citations Received

US Patent 11891365 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

0

US Patent 10870645 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

0

US Patent 10988450 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 11274085 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 11274084 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 11279681 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US Patent 11702412 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

0

Patent Primary Examiner

Niloofar Rahmani

0

Patent abstract

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10555935 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.